Hantz Financial Services’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$524K Buy
2,424
+267
+12% +$51.1K 0.01% 702
2026
Q1
$395K Buy
2,157
+321
+17% +$59.1K 0.01% 736
2025
Q4
$323K Buy
1,836
+200
+12% +$32.7K ﹤0.01% 697
2025
Q3
$229K Buy
1,636
+453
+38% +$61.2K ﹤0.01% 702
2025
Q2
$149K Buy
1,183
+1,153
+3,843% +$144K ﹤0.01% 668
2025
Q1
$4K Buy
+30
New +$4.29K ﹤0.01% 1193
2024
Q2
Sell
-26
Closed -$6K 1073
2024
Q1
$6K Hold
26
﹤0.01% 899
2023
Q4
$7K Sell
26
-40
-61% -$9.82K ﹤0.01% 859
2023
Q3
$17K Buy
66
+40
+154% +$10.7K ﹤0.01% 746
2023
Q2
$7K Hold
26
﹤0.01% 827
2023
Q1
$7K Hold
26
﹤0.01% 831
2022
Q4
$7K Hold
26
﹤0.01% 802
2022
Q3
$7K Hold
26
﹤0.01% 789
2022
Q2
$5K Sell
26
-3
-10% -$613 ﹤0.01% 837
2022
Q1
$6K Buy
+29
New +$6.31K ﹤0.01% 855

Other funds holding BIIB

Hantz Financial Services's BIIB Position: Q2 2026 in Review

Hantz Financial Services increased its Biogen (BIIB) stake by 12% in Q2 2026, buying an estimated $51.1K and bringing the position to 2,424 shares worth $524K. The position accounts for 0.01% of the portfolio, ranked #702.

Hantz Financial Services first reported a position in BIIB in Q1 2022 and has held it in 15 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Hantz Financial Services held 2,424 shares of Biogen worth $524K as of Q2 2026.
  • Hantz Financial Services bought 267 Biogen shares in Q2 2026, an estimated $51.1K.
  • Biogen made up 0.01% of Hantz Financial Services's portfolio in Q2 2026, its #702 holding.
  • Hantz Financial Services first reported a position in Biogen in Q1 2022 and has held it in 15 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.